Literature DB >> 35646368

A community-based approach to cervical cancer prevention in western Kenya: An AMPATH feasibility project.

Omenge Orang'o1,2, Philip Tonui1, Kapten Muthoka1, Stephen Kiptoo1, Titus Maina3, Mercy Agosa2, Aaron Ermel4, Yan Tong4, Darron Brown4.   

Abstract

Objectives: Centralized programs have been ineffective in reducing the burden of cervical cancer among Kenyan women. A community-based pilot study was initiated to screen Kenyan women for cervical cancer and to vaccinate their children against human papillomavirus (HPV).
Methods: Women were educated about cervical cancer prevention at community meetings. Women then provided self-collected vaginal swabs for oncogenic HPV testing using the Roche Cobas Assay. All women were then referred to the local clinic for Visual Inspection with Acetic Acid (VIA). Women were offered the quadrivalent HPV vaccine for their children if and when it became available for the study.
Results: Women in western Kenya were invited to participate in community meetings. A total of 200 women were enrolled: 151 (75.5%) were HIV-uninfected and 49 (24.5%) were HIV-infected; the median age for all women was 42 years. High-risk (HR)-HPV types were detected in 49 of swabs from all 200 participants (24.5%) including 20.5% of HIV-uninfected women and 36.7% of HIV-infected women (P = .022). VIA was performed on 198 women: 192 had normal examinations and six had abnormal examinations. Five cervical biopsies revealed two cases of CIN 2 and one CIN 3. Although all mothers were willing to have their children (N = 432) vaccinated, the HPV vaccine could not be delivered to Kenya during the study period. Conclusions: Kenyan women were willing to attend community meetings to learn about prevention of cervical cancer, to provide self-collected vaginal swabs for HPV testing, to travel to the Webuye Clinic for VIA following the collection of swabs, and to have their children vaccinated against HPV. HR-HPV was prevalent, especially in HIV-infected women. As a result of this pilot study, this community-based strategy to prevent cervical cancer will be continued in western Kenya.
© The Author(s) 2022.

Entities:  

Keywords:  Cervical cancer screening; HIV; Kenya; self-collected vaginal swabs

Year:  2022        PMID: 35646368      PMCID: PMC9134396          DOI: 10.1177/20503121221102111

Source DB:  PubMed          Journal:  SAGE Open Med        ISSN: 2050-3121


  20 in total

1.  Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.

Authors:  Susan Hariri; Nancy M Bennett; Linda M Niccolai; Sean Schafer; Ina U Park; Karen C Bloch; Elizabeth R Unger; Erin Whitney; Pamela Julian; Mary W Scahill; Nasreen Abdullah; Diane Levine; Michelle L Johnson; Martin Steinau; Lauri E Markowitz
Journal:  Vaccine       Date:  2015-02-11       Impact factor: 3.641

2.  Development and characterization of the cobas human papillomavirus test.

Authors:  Arundhati Rao; Stephen Young; Henry Erlich; Sean Boyle; Mark Krevolin; Rita Sun; Raymond Apple; Catherine Behrens
Journal:  J Clin Microbiol       Date:  2013-02-27       Impact factor: 5.948

3.  AMPATH: living proof that no one has to die from HIV.

Authors:  Thomas S Inui; Winston M Nyandiko; Sylvester N Kimaiyo; Richard M Frankel; Tadeo Muriuki; Joseph J Mamlin; Robert M Einterz; John E Sidle
Journal:  J Gen Intern Med       Date:  2007-10-31       Impact factor: 5.128

Review 4.  Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality.

Authors:  F Xavier Bosch; Silvia de Sanjosé
Journal:  J Natl Cancer Inst Monogr       Date:  2003

5.  Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya.

Authors:  Heleen Vermandere; Violet Naanyu; Hillary Mabeya; Davy Vanden Broeck; Kristien Michielsen; Olivier Degomme
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

6.  Good concordance of HPV detection between cervico-vaginal self-samples and general practitioner-collected samples using the Cobas 4800 HPV DNA test.

Authors:  Mette Tranberg; Jørgen Skov Jensen; Bodil Hammer Bech; Jan Blaakær; Hans Svanholm; Berit Andersen
Journal:  BMC Infect Dis       Date:  2018-07-27       Impact factor: 3.090

7.  Self-collected vaginal sampling for the detection of genital human papillomavirus (HPV) using careHPV among Ghanaian women.

Authors:  Dorcas Obiri-Yeboah; Yaw Adu-Sarkodie; Florencia Djigma; Anna Hayfron-Benjamin; Latif Abdul; Jacques Simpore; Philippe Mayaud
Journal:  BMC Womens Health       Date:  2017-09-26       Impact factor: 2.809

Review 8.  Human Papilloma Virus self-sampling performance in low- and middle-income countries.

Authors:  Ashwini Kamath Mulki; Mellissa Withers
Journal:  BMC Womens Health       Date:  2021-01-06       Impact factor: 2.809

9.  Uptake of three doses of HPV vaccine by primary school girls in Eldoret, Kenya; a prospective cohort study in a malaria endemic setting.

Authors:  Hillary Mabeya; Sonia Menon; Steven Weyers; Violet Naanyu; Emily Mwaliko; Elijah Kirop; Omenge Orango; Heleen Vermandere; Davy Vanden Broeck
Journal:  BMC Cancer       Date:  2018-05-11       Impact factor: 4.430

10.  Clinical evaluation and budget impact analysis of cervical cancer screening using cobas 4800 HPV screening technology in the public sector of South Africa.

Authors:  Greta Dreyer; Christopher Maske; Marthinus Stander
Journal:  PLoS One       Date:  2019-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.